BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3827 related articles for article (PubMed ID: 7425670)

  • 21. Immunotherapy for human malignant melanoma.
    Kopf AW
    South Med J; 1975 Apr; 68(4):495-503. PubMed ID: 1124416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human malignant melanoma antigenic properties of phenol water extracts.
    Suter L; Tilkorn H; Kövary PM
    Arch Dermatol Res; 1979 Feb; 264(1):37-47. PubMed ID: 443860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Leukocyte activation in advanced cancer as an explanation for absent leukocyte adherence inhibition to cancer extracts and chemoattractant.
    Labateya N; Thomson DM; Reid EC
    Eur J Cancer Clin Oncol; 1986 Jan; 22(1):33-43. PubMed ID: 3007156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leukocyte adherence inhibition by soluble tumor antigens in breast cancer patients.
    Fujisawa T; Waldman SR; Yonemoto RH
    Cancer; 1977 Feb; 39(2):506-13. PubMed ID: 65207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Study on the tumor immunity of renal cell carcinoma--with special reference to the significance of leukocyte adherence inhibition test].
    Okada Y
    Hinyokika Kiyo; 1984 Oct; 30(10):1367-77. PubMed ID: 6395679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of leukocyte glass adherence and tube leukocyte adherence inhibition (LAI) reactivity by serum factors in dogs with progressing or spontaneously regressing canine transmissible venereal sarcoma (CTVS).
    Harding MW; Yang TJ
    Cancer Immunol Immunother; 1985; 19(3):168-76. PubMed ID: 3891077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of leukocyte adherence by 3-M potassium chloride extracts of human colorectal tumors.
    Ichiki AT; Quirin YP; Collmann IR; Sonoda T; Krauss S
    J Natl Cancer Inst; 1980 Mar; 64(3):419-23. PubMed ID: 6986496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative cell-mediated immune status of patients with malignant glial tumors.
    Sheikh KM; Apuzzo ML; Weiss MH
    Neurol Res; 1979; 1(2):133-45. PubMed ID: 233266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of leukocyte migration by soluble tumor extracts in human malignant melanoma.
    Lapińska M; Jassem J; Kondrat W; Jaśkiewicz J
    Neoplasma; 1980; 27(1):37-42. PubMed ID: 6154899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-directed cellular immunity in malignant melanoma and its modification by surgical treatment.
    Cochran AJ; Thomas CE; Spilg WG; Grant RM; Cameron-Mowat DE; Mackie RM; Lindop G
    Yale J Biol Med; 1973 Dec; 46(5):650-4. PubMed ID: 4779137
    [No Abstract]   [Full Text] [Related]  

  • 31. A comparative study of natural cytotoxicity and the leukocyte migration inhibition in human melanoma stages I and II.
    Kristensen E
    J Cancer Res Clin Oncol; 1980; 96(2):181-91. PubMed ID: 7391115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Capillary tube leukocyte adherence inhibition: an assay for cell-mediated immunity in cancer patients.
    Urist MM; Boddie AW; Holmes EC; Morton DL
    Int J Cancer; 1976 Mar; 17(3):338-41. PubMed ID: 1254356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Leukocyte adherence inhibition as measured by a radioisotopic technique for detection of cell-mediated tumor immunity.
    Pierce GE; DeVald BL
    Int J Cancer; 1974 Dec; 14(6):833-9. PubMed ID: 4377009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunologic mechanisms in malignant melanoma of the skin.
    Cochran AJ
    Trans Ophthalmol Soc U K (1962); 1977 Sep; 97(3):385-8. PubMed ID: 347641
    [No Abstract]   [Full Text] [Related]  

  • 35. Changes in tumor immunity during therapy determined by leukocyte adherence inhibition and dermal testing.
    Vetto RM; Burger DR; Vandenbark AA; Finke PE
    Cancer; 1978 Mar; 41(3):1034-9. PubMed ID: 346188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective inhibition of leukocyte adherence in women with breast cancer using a variety of tissue extracts.
    Fritze D; Kaufmann M; Drings P; Fedra G
    Oncology; 1978; 35(6):242-5. PubMed ID: 370704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of the mechanism of the leukocyte adherence inhibition test.
    Tong AW; Burger DR; Finke P; Barney C; Vandenbark AA; Vetto RM
    Cancer Res; 1979 Feb; 39(2 Pt 2):597-603. PubMed ID: 367586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
    Cohen MH; Jessup JM; Felix EL; Weese JL; Herberman RB
    Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An immunological aspect of melanoma and its potential application in adjuvant therapy.
    Elias EG; Tomazic VJ
    J Surg Oncol; 1991 Dec; 48(4):220-3. PubMed ID: 1745045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effector lymphocyte response to homologous tumor antigens in various stages of malignant disease as monitored by leukocyte adherence inhibition--cell mediated immunity (LAI-CMI).
    Tsang PH; Roboz JP; Holland JF; Bekesi JG
    Immunol Lett; 1988 Jan; 17(1):63-70. PubMed ID: 3280478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 192.